CoChat

The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

Open access
Haczeyni, Fahrettin, Wang, Hans, Barn, Vanessa, Mridha, Auvro R., Yeh, Matthew M., Haigh, W. Geoffrey, Ioannou, George N., Choi, Yun‐Jung, McWherter, Charles A., Teoh, Narcissus C.‐H., Farrell, Geoffrey C. · 2017 · Hepatology Communications
Cited by 101

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis (NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed peroxisome proliferator–activated receptor‐alpha/delta (PPAR‐α/δ) agonists show some efficacy. Seladelpar (MBX‐8025), a selective PPAR‐δ agonist, improves atherogenic dyslipidemia. We therefore used this agent to test whether selective PPAR‐δ activation can reverse hepatic lipotoxicity and NASH in an obese, dyslipidemic, and diabetic mouse model. From weaning, female Alms1 mutant (foz/foz) mice and wild‐type littermates were fed an atherogenic diet for 16 weeks; groups (n = 8‐12) were then randomized to receive MBX‐8025 (10 mg/kg) or vehicle (1% methylcellulose) by gavage for 8 weeks. Despite minimally altering body weight, MBX‐8025 normalized hyperglycemia, hyperinsulinemia, and glucose disposal in foz/foz mice. Serum alanine aminotransferase ranged 300‐600 U/L in vehicle‐treated foz/foz mice; MBX‐8025 reduced alanine aminotransferase by 50%. In addition, MBX‐8025 normalized serum lipids and hepatic levels of free cholesterol and other lipotoxic lipids that were increased in vehicle‐treated foz/foz versus wild‐type mice. This abolished hepatocyte ballooning and apoptosis, substantially reduced steatosis and liver inflammation, and improved liver fibrosis. In vehicle‐treated foz/foz mice, the mean nonalcoholic fatty liver disease activity score was 6.9, indicating NASH; MBX‐8025 reversed NASH in all foz/foz mice (nonalcoholic fatty liver disease activity score 3.13). Conclusion: Seladelpar improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve NASH pathology in atherogenic diet–fed obese diabetic mice. Selective PPAR‐δ agonists act independently of weight reduction, but counter lipotoxicity related to insulin resistance, thereby providing a novel therapy for NASH. (Hepatology Communications 2017;1:663–674)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1072

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 33

  1. 2012, Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology, 56, 943, 10.1002/hep.25772 · DOI · Paper page
  2. 2013, NAFLD in Asia—as common and important as in the West, Nat Rev Gastroenterol Hepatol, 10, 307, 10.1038/nrgastro.2013.34 · DOI · Paper page
  3. 2011, Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis, Gastroenterology, 141, 1393, 10.1053/j.gastro.2011.06.040 · DOI · Paper page
  4. 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003 · DOI · Paper page
  5. 2012, Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease, Cell Metab, 15, 665, 10.1016/j.cmet.2012.04.004 · DOI · Paper page
  6. 2015, Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents, J Gastroenterol Hepatol, 30, 163, 10.1111/jgh.12666 · DOI
  7. 2015, Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
  8. 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 · DOI · Paper page
  9. 2016, Non‐alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies, Nat Rev Drug Discov, 15, 249, 10.1038/nrd.2015.3 · DOI · Paper page
  10. 2017, Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice, Obesity, 25, 155, 10.1002/oby.21701 · DOI · Paper page
  11. 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016/j.jhep.2015.02.041 · DOI · Paper page
  12. 2015, Peroxisome proliferator–activated receptors as targets to treat non‐alcoholic fatty liver disease, World J Hepatol, 7, 1012, 10.4254/wjh.v7.i8.1012 · DOI · Paper page
  13. 2012, A myriad of pathways to NASH, Clin Liver Dis, 16, 525, 10.1016/j.cld.2012.05.009 · DOI
  14. 2011, The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact, Trends Pharmacol Sci, 32, 607, 10.1016/j.tips.2011.06.006 · DOI
  15. 2013, Peroxisome proliferator–activated receptor delta and cardiovascular disease, Atherosclerosis, 231, 95, 10.1016/j.atherosclerosis.2013.08.027 · DOI
  16. 2008, Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity‐induced insulin resistance, Cell Metab, 7, 496, 10.1016/j.cmet.2008.04.003 · DOI · Paper page
  17. 2012, Lipid effects of peroxisome proliferator–activated receptor‐Δ agonist GW501516 in subjects with low high‐density lipoprotein cholesterol characteristics of metabolic syndrome, Arterioscler Thromb Vasc Biol, 32, 2289, 10.1161/ATVBAHA.112.247890 · DOI · Paper page
  18. 2011, Mechanism of action of a peroxisome proliferator–activated receptor (PPAR)‐δ agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity, J Clin Endocrinol Metab, 96, E1568, 10.1210/jc.2011-1131 · DOI
  19. 2014, GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes, Expert Opin Investig Drugs, 23, 1441, 10.1517/13543784.2014.954034 · DOI
  20. 2012, Effects of the PPAR‐δ agonist MBX‐8025 on atherogenic dyslipidemia, Atherosclerosis, 220, 470, 10.1016/j.atherosclerosis.2011.10.029 · DOI
  21. 2011, MBX‐8025, a novel peroxisome proliferator receptor‐δ agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin, J Clin Endocrinol Metab, 96, 2889, 10.1210/jc.2011-1061 · DOI · Paper page
  22. 2008, Activation of peroxisome proliferator–activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men, Diabetes, 57, 332, 10.2337/db07-1318 · DOI · Paper page
  23. 2013, Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome, J Hepatol, 59, 144, 10.1016/j.jhep.2013.02.024 · DOI
  24. 2015, Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice, Obesity, 23, 1845, 10.1002/oby.21170 · DOI · Paper page
  25. 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  26. 2007, Discovery of para‐alkylthiophenoxyacetic acids as a novel series of potent and selective PPARδ agonists, Bioorg Med Chem Lett, 17, 3855, 10.1016/j.bmcl.2007.05.007 · DOI
  27. 2014, Hepatocyte free cholesterol lipotoxicity results from JNK1‐mediated mitochondrial injury and is HMGB1 and TLR4‐dependent, J Hepatol, 61, 1376, 10.1016/j.jhep.2014.07.024 · DOI · Paper page
  28. 2004, Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18, Cancer Res, 64, 1751, 10.1158/0008-5472.CAN-03-2455 · DOI · Paper page
  29. 2013, Desnutrin/ATGL activates PPARδ to promote mitochondrial function for insulin secretion in islet β cells, Cell Metab, 18, 883, 10.1016/j.cmet.2013.10.012 · DOI · Paper page
  30. 2014, Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice, Am J Physiol Endocrinol Metab, 306, E945, 10.1152/ajpendo.00473.2013 · DOI · Paper page
  31. 2006, Activation of PPAR‐δ in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids, Diabetologia, 49, 2713, 10.1007/s00125-006-0357-6 · DOI
  32. 2014, New peroxisome proliferator–activated receptor agonists: potential treatments for atherogenic dyslipidemia and non‐alcoholic fatty liver disease, Expert Opin Pharmacother, 15, 493, 10.1517/14656566.2014.876992 · DOI · Paper page
  33. 2008, PPAR‐β/δ agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home, Expert Opin Investig Drugs, 17, 1465, 10.1517/13543784.17.10.1465 · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Haczeyni, F., Wang, H., Barn, V., Mridha, A. R., Yeh, M. M., Haigh, W. G., Ioannou, G. N., Choi, Y., McWherter, C. A., Teoh, N. C. ‐., & Farrell, G. C.
Venue
Hepatology Communications
Published
2017-07-31
Volume
1
Issue
7
Pages
663-674
ISSN
2471-254X (ISSN-L)
OpenAlex
W2741416895
Cited by
101
References
10
FWCI
6.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. https://app.cochat.ai/papers/10.1002/hep4.1072
The paper
Haczeyni, F., Wang, H., Barn, V., Mridha, A. R., Yeh, M. M., Haigh, W. G., Ioannou, G. N., Choi, Y., McWherter, C. A., Teoh, N. C. ‐., & Farrell, G. C. (2017). The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatology Communications. https://doi.org/10.1002/hep4.1072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.